Author
Listed:
- Michael A. Crackower
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto
University of Toronto
The Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research, University of Toronto)
- Renu Sarao
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto
IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences)
- Gavin Y. Oudit
(The Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research, University of Toronto
University of Toronto
University of Toronto)
- Chana Yagil
(Faculty of Health Science, Ben-Gurion University Barzilai Medical Center Campus)
- Ivona Kozieradzki
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto
IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences)
- Sam E. Scanga
(University Health Network, Ontario Cancer Institute, University of Toronto)
- Antonio J. Oliveira-dos-Santos
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto)
- Joan da Costa
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto)
- Liyong Zhang
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto
University of Toronto
The Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research, University of Toronto
IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences)
- York Pei
(University of Toronto)
- James Scholey
(University of Toronto)
- Carlos M. Ferrario
(The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine)
- Armen S. Manoukian
(University Health Network, Ontario Cancer Institute, University of Toronto)
- Mark C. Chappell
(The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine)
- Peter H. Backx
(The Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research, University of Toronto
University of Toronto
University of Toronto)
- Yoram Yagil
(University of Toronto)
- Josef M. Penninger
(Amgen Research Institute/Ontario Cancer Institute, University of Toronto
University of Toronto
The Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research, University of Toronto
IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences)
Abstract
Cardiovascular diseases are predicted to be the most common cause of death worldwide by 2020. Here we show that angiotensin-converting enzyme 2 (ace2) maps to a defined quantitative trait locus (QTL) on the X chromosome in three different rat models of hypertension. In all hypertensive rat strains, ACE2 messenger RNA and protein expression were markedly reduced, suggesting that ace2 is a candidate gene for this QTL. Targeted disruption of ACE2 in mice results in a severe cardiac contractility defect, increased angiotensin II levels, and upregulation of hypoxia-induced genes in the heart. Genetic ablation of ACE on an ACE2 mutant background completely rescues the cardiac phenotype. But disruption of ACER, a Drosophila ACE2 homologue, results in a severe defect of heart morphogenesis. These genetic data for ACE2 show that it is an essential regulator of heart function in vivo.
Suggested Citation
Michael A. Crackower & Renu Sarao & Gavin Y. Oudit & Chana Yagil & Ivona Kozieradzki & Sam E. Scanga & Antonio J. Oliveira-dos-Santos & Joan da Costa & Liyong Zhang & York Pei & James Scholey & Carlos, 2002.
"Angiotensin-converting enzyme 2 is an essential regulator of heart function,"
Nature, Nature, vol. 417(6891), pages 822-828, June.
Handle:
RePEc:nat:nature:v:417:y:2002:i:6891:d:10.1038_nature00786
DOI: 10.1038/nature00786
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Tomokazu Yamaguchi & Midori Hoshizaki & Takafumi Minato & Satoru Nirasawa & Masamitsu N. Asaka & Mayumi Niiyama & Masaki Imai & Akihiko Uda & Jasper Fuk-Woo Chan & Saori Takahashi & Jianbo An & Akari , 2021.
"ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury,"
Nature Communications, Nature, vol. 12(1), pages 1-13, December.
- Milad Haghani & Pegah Varamini, 2021.
"Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature,"
Scientometrics, Springer;Akadémiai Kiadó, vol. 126(8), pages 7005-7050, August.
- Joshua M Akey & Michael A Eberle & Mark J Rieder & Christopher S Carlson & Mark D Shriver & Deborah A Nickerson & Leonid Kruglyak, 2004.
"Population History and Natural Selection Shape Patterns of Genetic Variation in 132 Genes,"
PLOS Biology, Public Library of Science, vol. 2(10), pages 1-1, September.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:417:y:2002:i:6891:d:10.1038_nature00786. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.